HK1017671A1 - Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents - Google Patents

Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents

Info

Publication number
HK1017671A1
HK1017671A1 HK99102896A HK99102896A HK1017671A1 HK 1017671 A1 HK1017671 A1 HK 1017671A1 HK 99102896 A HK99102896 A HK 99102896A HK 99102896 A HK99102896 A HK 99102896A HK 1017671 A1 HK1017671 A1 HK 1017671A1
Authority
HK
Hong Kong
Prior art keywords
derivatives
compounds
ene
therapeutic agents
substituted
Prior art date
Application number
HK99102896A
Other languages
English (en)
Inventor
Robert M Burk
Original Assignee
Allergan Sales Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales Inc filed Critical Allergan Sales Inc
Publication of HK1017671A1 publication Critical patent/HK1017671A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Fats And Perfumes (AREA)
  • Cosmetics (AREA)
HK99102896A 1996-02-29 1999-07-07 Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents HK1017671A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/608,794 US5741810A (en) 1996-02-29 1996-02-29 Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
PCT/US1997/002313 WO1997031895A2 (en) 1996-02-29 1997-02-20 Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents

Publications (1)

Publication Number Publication Date
HK1017671A1 true HK1017671A1 (en) 1999-11-26

Family

ID=24438034

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99102896A HK1017671A1 (en) 1996-02-29 1999-07-07 Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents

Country Status (13)

Country Link
US (4) US5741810A (xx)
EP (1) EP0888298B1 (xx)
JP (1) JP4226650B2 (xx)
KR (1) KR19990087352A (xx)
CN (1) CN1133434C (xx)
AT (1) ATE220664T1 (xx)
AU (1) AU725145B2 (xx)
BR (1) BR9707892A (xx)
CA (1) CA2247208A1 (xx)
DE (1) DE69714023T2 (xx)
ES (1) ES2178756T3 (xx)
HK (1) HK1017671A1 (xx)
WO (1) WO1997031895A2 (xx)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124344A (en) * 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
WO1998021180A1 (en) * 1995-06-07 1998-05-22 Alcon Laboratories, Inc. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
US5741810A (en) 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
EP1012136B1 (en) * 1997-09-09 2004-07-07 Duke University Aromatic c 16?-c 20?-substituted tetrahydro prostaglandins useful as fp agonists
WO1999012898A1 (en) * 1997-09-09 1999-03-18 The Procter & Gamble Company Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
PL339213A1 (en) * 1997-09-09 2000-12-04 Procter & Gamble Aromatic c16-c20-substituted tetrahydroprostaglandines useful as fp agonists
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
ATE281432T1 (de) 1999-03-05 2004-11-15 Univ Duke C-16 ungesätigte fp-selektive prostaglandin analoge
WO2000051616A1 (en) * 1999-03-05 2000-09-08 The Procter & Gamble Company Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
US6826874B2 (en) * 1999-06-30 2004-12-07 Nippon Steel Corporation Buckling restrained braces and damping steel structures
JP4000505B2 (ja) 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) * 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US6248783B1 (en) * 2000-09-20 2001-06-19 Allergan Sales, Inc. Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents
US6531504B2 (en) * 2001-05-17 2003-03-11 Allergan, Inc. Prostanoic acid derivatives as agents for lowering intraocular pressure
US6476064B1 (en) * 2001-06-13 2002-11-05 Allergan, Inc. Cyclopentane heptan(ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
BR0202157A (pt) * 2002-06-07 2005-04-12 Univ Minas Gerais Peptìdeo obtido de veneno escorpião para uso como agente hipotensivo
US7179820B2 (en) * 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
JP2005511607A (ja) * 2003-07-10 2005-04-28 アラーガン、インコーポレイテッド ＥＰ２受容体作動剤としてのω−シクロアルキル１７−ヘテロアリールプロスタグランジンＥ２類似体
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
US7101904B2 (en) * 2004-08-10 2006-09-05 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7906552B2 (en) 2004-08-10 2011-03-15 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
AU2006311942B2 (en) * 2005-11-03 2012-11-22 Allergan, Inc. Prostaglandins and analogues as agents for lowering intraocular pressure
CN103755737A (zh) * 2006-02-07 2014-04-30 株式会社·R-技术上野 用于制备前列腺素衍生物的方法
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
KR20180021919A (ko) 2009-11-09 2018-03-05 알러간, 인코포레이티드 모발 성장을 촉진하기 위한 조성물 및 방법
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
US8783923B2 (en) * 2010-03-18 2014-07-22 Chung Yuan Christian University Auto lamp structure
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
EP3563882A1 (en) 2013-03-15 2019-11-06 Allergan, Inc. Prostamide-containing intraocular implant
DK2981248T3 (da) 2013-04-01 2020-11-30 Allergan Inc Mikrosfærelægemiddelleveringssystem til langvarig intraokulær frigivelse
EP4046628A1 (en) 2013-10-31 2022-08-24 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
BR112017023316A2 (pt) 2015-04-30 2018-08-14 Allergan, Inc. método cosmético e uso terapêutico para redução de gordura
BR112023001073A2 (pt) 2020-07-21 2023-03-07 Allergan Inc Implante intraocular com alto carregamento de prostamida

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3781325A (en) * 1971-05-04 1973-12-25 Upjohn Co 15-methoxy-pgf2a
US3845115A (en) * 1971-05-04 1974-10-29 Upjohn Co 15-lower alkoxy pgf compounds
BE786251A (fr) * 1971-07-14 1973-01-15 Ici Ltd Nouveaux derives du cyclopentane
US4102894A (en) * 1975-11-19 1978-07-25 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandins
US3974213A (en) * 1972-07-13 1976-08-10 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins
US3956284A (en) * 1972-07-13 1976-05-11 Pfizer Inc. Heterocyclic 15-substituted-ω-pentanorprostoglandins
US4113723A (en) * 1972-07-13 1978-09-12 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandins
US3980642A (en) * 1972-07-13 1976-09-14 Pfizer Inc. 15-Substitute D-ω-pentanorprostaglandins
DE2353159A1 (de) * 1972-07-13 1975-03-13 Pfizer Ketophosphonate und verfahren zu deren herstellung
US3984424A (en) * 1972-11-08 1976-10-05 Pfizer Inc. P-biphenyl esters of 15-substituted-ω-pentanorprostaglandins
US4036832A (en) * 1974-07-03 1977-07-19 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandins
IT1053781B (it) * 1974-09-25 1981-10-10 Erba C S P A Ora Farmitalia Omega nor cicloalcil 13.14 deidro prostaglandine
IT1088966B (it) * 1977-11-15 1985-06-10 Erba Carlo Spa 13,14-dideidro-prostaglandine
DE3125271A1 (de) * 1981-06-24 1983-01-13 Schering Ag, 1000 Berlin Und 4619 Bergkamen (delta)(pfeil hoch)8(pfeil hoch),(pfeil hoch)9(pfeil hoch)-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB8329559D0 (en) * 1983-11-04 1983-12-07 Erba Farmitalia Furyl derivatives of 16-substituted prostaglandins preparations
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
CA2021316C (en) * 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5028624A (en) * 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US5034413A (en) * 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5834498A (en) 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
AU665287B2 (en) * 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5545665A (en) * 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
AU693698B2 (en) * 1995-05-18 1998-07-02 Allergan, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylakenyl derivatives as therapeutic agents for the treatment of ocular hypertension
US5741810A (en) * 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents

Also Published As

Publication number Publication date
US20030191178A1 (en) 2003-10-09
AU1958597A (en) 1997-09-16
ES2178756T3 (es) 2003-01-01
BR9707892A (pt) 1999-07-27
CA2247208A1 (en) 1997-09-04
US6096902A (en) 2000-08-01
CN1133434C (zh) 2004-01-07
EP0888298A2 (en) 1999-01-07
US20010029304A1 (en) 2001-10-11
US5741810A (en) 1998-04-21
WO1997031895A3 (en) 1997-12-18
US6573390B2 (en) 2003-06-03
US6680337B2 (en) 2004-01-20
ATE220664T1 (de) 2002-08-15
JP2000506139A (ja) 2000-05-23
DE69714023T2 (de) 2003-03-13
DE69714023D1 (en) 2002-08-22
AU725145B2 (en) 2000-10-05
KR19990087352A (ko) 1999-12-27
EP0888298B1 (en) 2002-07-17
JP4226650B2 (ja) 2009-02-18
CN1218400A (zh) 1999-06-02
WO1997031895A2 (en) 1997-09-04

Similar Documents

Publication Publication Date Title
HK1017671A1 (en) Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
CA2242991A1 (en) Use of antioxidant agents to treat cholestatic liver disease
NZ337769A (en) Methods and compositions for modulating responsiveness to corticosteroids
CA2354695A1 (en) Compositions and methods for amelioration of human female sexual dysfunction
EP1602369A3 (en) Bupropion Metabolites and Methods of their Synthesis and Use
CL2010000383A1 (es) Esteres y amida de acidos carboxilicos que contienen un agente anti-inflamatorio no esteroidal; composicion farmaceutica: y su uso como inhibidores de 5-lipoxigenasa para prevenir o aliviar edema de tejidos, inflamacion y congestion de la conjuntiva, de la nubosidad de la cornea y daños a tejidos oftalmicos (divisional sol. 3109-99).
WO1999011275A3 (en) Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
BR9907189A (pt) Produtos da fração lipìdica do carotenóide de pepino do mar e métodos de uso
ID26042A (id) Turunan-turunan asam lemak dari asam-asam empedu dan asam empedu
WO2000028999A3 (en) Methods of treating tardive dyskinesia and other movement disorders
ES2130268T3 (es) Preparados de acido hialuronico de bajo peso molecular, para estimulacion de formacion de huesos.
HK1027748A1 (en) Use of 3-benzoyl-phenylacetic acids, esters, or amides for treatment of glcia glaucoma
AR000271A1 (es) Composiciones cosméticas par uso tópico utilizables para el bronceado y/o el tostado artificiales dela piel
EP0738152A4 (en) USE OF 2-HYDROXY-5-PHENYLAZOBOIC ACID DERIVATIVES AS ACTIVE SUBSTANCES FOR CHEMOPREVENTION AND CHEMOTHERAPY OF COLON CANCER
BR9811099A (pt) Inibidores de urocinase
GR3035689T3 (en) Ether lipid liposomes and their therapeutic use
ZA967880B (en) Compositions and methods for inhibition of the patho-physiologic actions in mammals in tumor necrosis facto-alpha
AU1438699A (en) Fatty acid uninterrupted by a methylene as anti-inflammatory agents in superficial tissues of mammals
BR9712283A (pt) Método para inibir as cinases de proteìnas ativadas por tensão
GB2330533A (en) Composition for enhanced uptake of polar drugs from mucosal surfaces
DOP2002000356A (es) Conjugados de pregabalina lactosa
BG102342A (en) Optical active derivative of phenylpyrimidine as an anlgesics
ES2175669T3 (es) Nuevos prepolimeros terminados en isocianato.
WO2000038690A3 (en) Prostaglandin e agonists for treatment of dry eye
BR9809376A (pt) Pregnan-3-ol-20-onas

Legal Events

Date Code Title Description
AS Change of ownership

Owner name: ALLERGAN, INC.

Free format text: FORMER OWNER(S): ALLERGAN SALES, LLC

Owner name: ALLERGAN SALES, LLC

Free format text: FORMER OWNER(S): ALLERGAN SALES, INC

PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090220